E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hepatic resection or soft tissue dissection |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042609 |
E.1.2 | Term | Surgery |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the efficacy of topical Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, in surgical subjects when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical
|
|
E.2.2 | Secondary objectives of the trial |
To characterize the safety of topical Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, in surgical subjects when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria (pre-surgery) 1. Male or female ≥ 18 years of age 2. Subjects who are able and willing to provide written and signed informed consent 3. Willing to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits 4. Has a life expectancy of at least one year Inclusion Criteria (during surgery) 5. Presence of mild or moderate bleeding/oozing and control by conventional surgical techniques including but not limited to suture, ligature, and cautery is ineffective or impractical 6. Absence of intra-operative complications other than bleeding which, in the opinion of the Investigator, may interfere with the assessment of efficacy or safety 7. No intra-operative use of a topical hemostat containing thrombin 8. Target Bleeding Site surface area of ≤ 100 cm2
|
|
E.4 | Principal exclusion criteria |
1. Pregnant or lactating women 2. Has a known intolerance to blood products or to Fibrocaps components 3. Unwilling to receive human blood products 4. Subject has a known allergy to porcine gelatin 5. Has a mental or physical condition that would, in the opinion of the Investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol 6. Currently participating or has participated in another clinical study involving another investigational agent within 4 weeks of the planned date of surgery, or is planning participation in another clinical trial during the 4 weeks after surgery 7. Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the Investigator 8. Aspartate Aminotransferase or Alanine aminotransferase (AST/ASAT or ALT/ALAT) > 3 x upper limit normal range during screening, except for subjects undergoing liver resection where there is no upper limit for these analytes due to the nature of their disease 9. Platelets < 100 x10E9 PLT/L during screening 10. aPTT > 100 seconds during screening 11. INR > 2.5 during screening
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy: 1°: Mean Time to Hemostasis (TTH) of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone 2°: Proportion of subjects achieving hemostasis at 3, 5, and 10 minutes
Safety: Compare the overall safety and tolerability of Fibrocaps plus gelatin sponge and gelatin sponge alone, as determined by: • The incidence and severity of treatment-emergent adverse events • The incidence and grade of treatment-emergent clinical laboratory abnormalities • Proportion of subjects developing anti-thrombin antibodies |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is defined as last visit of the last subject in the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |